FENNEC PHARMACEUTICALS INC.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
FENC$10.83+10.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(U.S. dollars and shares in thousands)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · December 31, · · December 31, | ||||||
| · · 2025 · · 2024 | ||||||
| | | | | | | |
| Assets · · · · · | ||||||
| Current assets · · · · · | ||||||
| Cash and cash equivalents | | $36,788 | | $26,634 | ||
| Accounts receivable, net | | | 23,221 | | | 12,884 |
| Prepaid expenses | | 3,738 | | 3,080 | ||
| Inventory | | | 1,565 | | | 1,060 |
| Other current assets | | 1,731 | | 466 | ||
| Total current assets | | | 67,043 | | | 44,124 |
| | | | | | | |
| Non-current assets | | | | | | |
| Non-current accounts receivable, net | | | 2,791 | | | — |
| Other non-current assets, net of amortization | | | 717 | | | 822 |
| Total non-current assets | | | 3,508 | | | 822 |
| Total assets | | $70,551 | | $44,946 | ||
| | | | | | ||
| Liabilities and shareholders’ equity/(deficit) | | | | | ||
| Current liabilities: | | | | | ||
| Accounts payable | | $4,635 | | $3,241 | ||
| Accrued liabilities | | 5,635 | | 3,428 | ||
| Operating lease liability - current | | | — | | | 2 |
| Contract liability - current | | | 248 | | | 248 |
| Total current liabilities | | 10,518 | | 6,919 | ||
| | | | | | | |
| Non-current liabilities | | | | | | |
| Term loan | | | — | | | 18,206 |
| PIK interest | | | — | | | 1,271 |
| Debt discount | | | — | | | (139) |
| Contract liability - long-term | | | 24,561 | | | 24,561 |
| Total non-current liabilities | | | 24,561 | | | 43,899 |
| Total liabilities | | 35,079 | | 50,818 | ||
| | | | | | ||
| Commitments and contingencies (Note 7) | | | | | ||
| | | | | | ||
| Shareholders’ equity/(deficit) | | | | | ||
| Common stock, no par value; unlimited shares authorized; 34,163 shares issued and outstanding (2024 ‑ 27,527) | | 189,906 | | 145,608 | ||
| Additional paid-in capital | | 73,745 | | 66,958 | ||
| Accumulated deficit | | (229,422) | | (219,681) | ||
| Accumulated other comprehensive income | | 1,243 | | 1,243 | ||
| Total shareholders’ equity/(deficit) | | 35,472 | | (5,872) | ||
| Total liabilities and shareholders’ equity/(deficit) | | $70,551 | | $44,946 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.